secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021739
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences reports positive MISSION Phase 2 results: 64.7% ORR at Week 25, increases to 94.1% in follow-up
--------------------------------------------------------------------------------

- ORR (≥50% proteinuria reduction) in 11/17 patients (64.7%) at Week 25; increased to 94.1% at Week 29 and 88.2% at Week 37.
- CRR (UPCR ≤0.5) achieved in 35.3% at end of treatment, rising to 41.2% during safety follow-up (Week 29 & 37).
- Mean background corticosteroid use reduced by 53%; by Week 13, 82.4% on ≤10 mg/day steroids.
- SLEDAI-2K reduced from 11.3 baseline to 6.5 at EOT; Physician Global Assessment from 57.2 to 23.9.
- Zetomipzomib well-tolerated; no Grade 3 infections; early terminations in 4/21 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022021739/0000950170-22-021739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022021739/kzr-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer